Abstract
Background: Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88–98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC.
Objective: The present review reports a detailed description of epigenetic abnormalities (DNA methylation, histone modifications and miRNA profile), probably involved in the pathogenesis and progression of MTC.
Methods: A systematic review was performed using Pubmed and Google patents databases. Results: We report the current understanding of epigenetic patterns in MTC and discuss the potential use of current knowledge in designing novel therapeutic strategies through epigenetic drugs, focusing on recent patents in this field.
Conclusion: Taking into account the reversibility of epigenetic alterations and the recent development in this field, epigenetic therapy may emerge for clinical use in the near future for patients with advanced MTC.
Keywords: DNA methylation, epigenetics, epigenetic therapy, histone modifications, medullary thyroid cancer, microRNA.
Recent Patents on Anti-Cancer Drug Discovery
Title:Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy
Volume: 11 Issue: 3
Author(s): Giovanni Vitale, Alessandra Dicitore, Erika Messina, Concetta Sciammarella, Antongiulio Faggiano and Annamaria Colao
Affiliation:
Keywords: DNA methylation, epigenetics, epigenetic therapy, histone modifications, medullary thyroid cancer, microRNA.
Abstract: Background: Medullary thyroid carcinoma (MTC) originates from the parafollicular C cells of the thyroid gland. Mutations of the RET proto-oncogene are implicated in the pathogenesis of MTC. Germline activating mutations of this gene have been reported in about 88–98% of familial MTCs, while somatic mutations of RET gene have been detected in about 23-70% of sporadic forms. Although these genetic events are well characterized, much less is known about the role of epigenetic abnormalities in MTC.
Objective: The present review reports a detailed description of epigenetic abnormalities (DNA methylation, histone modifications and miRNA profile), probably involved in the pathogenesis and progression of MTC.
Methods: A systematic review was performed using Pubmed and Google patents databases. Results: We report the current understanding of epigenetic patterns in MTC and discuss the potential use of current knowledge in designing novel therapeutic strategies through epigenetic drugs, focusing on recent patents in this field.
Conclusion: Taking into account the reversibility of epigenetic alterations and the recent development in this field, epigenetic therapy may emerge for clinical use in the near future for patients with advanced MTC.
Export Options
About this article
Cite this article as:
Vitale Giovanni, Dicitore Alessandra, Messina Erika, Sciammarella Concetta, Faggiano Antongiulio and Colao Annamaria, Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (3) . https://dx.doi.org/10.2174/1574892811666160614115356
DOI https://dx.doi.org/10.2174/1574892811666160614115356 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Composite Lymphomas: A Challenging Entity
Current Cancer Therapy Reviews Harnessing the Power of Cerenkov Luminescence Imaging for Gastroenterology: Cerenkov Luminescence Endoscopy
Current Medical Imaging An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Estrogen Regulation of Adipose Tissue Functions: Involvement of Estrogen Receptor Isoforms
Infectious Disorders - Drug Targets Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Sulforaphane Treatment of Young Men with Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas
Current Clinical Pharmacology The Role of Parathyroid Hormone-Related Protein (PTHrP) in the Pathophysiology of Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Lymphoproliferative Disorders and Chemokines
Current Drug Targets Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
Current Medicinal Chemistry Impact of Antioxidant Natural Compounds on the Thyroid Gland and Implication of the Keap1/Nrf2 Signaling Pathway
Current Pharmaceutical Design Angiogenic Growth Factors and their Inhibitors in Diabetic Retinopathy
Current Diabetes Reviews Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology